$The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma$

The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma

Summary As a result of the anti‐tumour activity observed in vitro and in vivo with combined anti‐CD20 and anti‐CD74 antibodies, we initiated a phase I/II trial of veltuzumab and milatuzumab in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma (NHL). Patients received an induction of v...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2015-06, Vol.169 (5), p.701-710
Hauptverfasser:	Christian, Beth A., Poi, Ming, Jones, Jeffrey A., Porcu, Pierluigi, Maddocks, Kami, Flynn, Joseph M., Benson, Don M., Phelps, Mitch A., Wei, Lai, Byrd, John C., Wegener, William A., Goldenberg, David M., Baiocchi, Robert A., Blum, Kristie A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use B-Lymphocytes - pathology extended dosing Female Humans Lymphoma, Non-Hodgkin - diagnosis Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - mortality Lymphoma, Non-Hodgkin - pathology Male Middle Aged milatuzumab monoclonal antibody Neoplasm Grading non‐Hodgkin lymphoma Treatment Outcome veltuzumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!